China is in negotiations with Pfizer Inc. to get a license that will allow domestic drugmakers to produce and market a generic version of the COVID-19 antiviral medicine Paxlovid in China, according to three sources cited by Reuters. Since late last month, China’s National Medical Products Administration (NMPA) has been in charge of negotiations with Pfizer, according to one source …
